Teva has filed an application with the US Supreme Court to stay a ruling by the US Court of Appeals for the Federal Circuit that allowed generic drug makers to enter the market before the expiry of Teva’s patents covering its $4.3 billion-a-year multiple sclerosis drug Copaxone.
Mumbai-based Sun Pharmaceutical Industries is buying Indian rival Ranbaxy Laboratories in a merger worth $3.2 billion, the companies have confirmed.
Generic drug maker Prasco Laboratories has agreed to market and distribute an authorised generic version of Eli Lilly’s Evista (raloxifene hydrochloride) in the US.
The US Court of Appeals for the Federal Circuit has reversed a lower court decision that found Actavis’s generic version of Shire’s ulcerative colitis drug Lialda (mesalamine) infringes US patent 6,773,720.
The US District Court for the Southern District of Indiana has upheld a patent covering Eli Lilly’s second biggest drug Alimta (pemetrexed disodium), after a challenge by Teva’s US pharmaceutical arm.
The US Supreme Court has agreed to hear Teva’s appeal against a Federal Circuit decision that invalidated a patent covering its $4.3 billion-a-year Copaxone (glatiramer acetate) drug, allowing Sandoz, Mylan and Natco to produce generic versions.
Novartis has sued generic drugmaker Dr. Reddy’s Laboratories for infringing a patent related to its chronic myelogenous leukaemia drug Gleevec/Glivec (imatinib mesylate).
The US District Court for the Northern District of West Virginia has upheld the validity of four patents covering Mylan’s Perforomist (formoterol fumarate) inhalation solution.
Teva-owned subsidiary Cephalon has sued Sun Pharma, claiming the Mumbai-based firm infringed a patent protecting its Treanda (bendamustine hydrochloride) product.
Pfizer has filed patent infringement suits against India-based Torrent Pharmaceuticals in an attempt to stop it selling a generic version of erectile dysfunction drug Viagra (sildenafil citrate).